Biomarkers in diabetic retinopathy and the therapeutic implications

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Zorena, Katarzyna ^a   Raczyńska, Dorota ^b   Raczyńska, Krystyna ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AFLIBERCEPT; BEVACIZUMAB; BIOLOGICAL MARKER; CERTOLIZUMAB PEGOL; ETANERCEPT; FIBROBLAST GROWTH FACTOR 2; GLITAZONE DERIVATIVE; GOLIMUMAB; IMATINIB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; LOSARTAN; METALLOPROTEINASE; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; RECOMBINANT GAMMA INTERFERON; RITUXIMAB; SCATTER FACTOR; SIMPON 1; SOMATOMEDIN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; APTAMER; EYE PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BEHCET DISEASE; BIOLOGICAL ACTIVITY; CHORIORETINOPATHY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE INFLAMMATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LASER COAGULATION; LOW LEVEL LASER THERAPY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; RETINA VASCULITIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; VISUAL ACUITY; VITRECTOMY; WEGENER GRANULOMATOSIS; ANIMAL; DRUG ANTAGONISM; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; QUALITY OF LIFE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; APTAMERS, NUCLEOTIDE; BIOLOGICAL MARKERS; DIABETIC RETINOPATHY; EYE PROTEINS; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-12; MICE; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SERPINS; SOMATOMEDINS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84889061465     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/193604     Document Type: Review

References (136)

1. Ginter E., Simko V., Global prevalence and future of diabetes mellitus. Advances in Experimental Medicine and Biology 2012 771 35 41
2. Magee M. J., Narayan K. M., Global confluence of infectious and non-communicable diseases-the case of type 2 diabetes. Preventive Medicine 2013 57 3 149 151 10.1016/j.ypmed.2013.05.027
3. Jarosz-Chobot P., Polanska J., Szadkowska A., Kretowski A., Bandurska-Stankiewicz E., Ciechanowska M., Deja G., Mysliwiec M., Peczynska J., Rutkowska J., Sobel-Maruniak A., Fichna P., Chobot A., Rewers M., Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. Diabetologia 2011 54 3 508 515 2-s2.0-79953757810 10.1007/s00125-010-1993-4
4. Romero-Aroca P., Mendez-Marin I., Baget-Bernaldiz M., Fernández-Ballart J., Santos-Blanco E., Review of the relationship between renal and retinal microangiopathy in diabetes mellitus patients. Current Diabetes Reviews 2010 6 2 88 101 2-s2.0-77950797377 10.2174/157339910790909387
5. Pant R., Marok R., Klein L. W., Pathophysiology of coronary vascular remodeling: relationship with traditional risk factors for coronary artery disease. Cardiology in Review. In press
6. Hamasaki H., Moriyama S., Yanai H., A crosstalk between macroangiopathy and microangiopathy in type 2 diabetes. International Journal of Cardiology 2013 168 1 550 551 10.1016/j.ijcard.2013.01.199
7. de Almeida Salgado P. P. C., Silva I. N., Vieira E. C., Silva A. C. S. E., Risk factors for early onset of diabetic nephropathy in pediatric type 1 diabetes. Journal of Pediatric Endocrinology and Metabolism 2010 23 12 1311 1320 2-s2.0-79955498642 10.1515/jpem.2010.205
8. Trento M., Passera P., Trevisan M., Schellino F., Sitia E., Albani S., Montanaro M., Bandello F., Scoccianti L., Charrier L., Cavallo F., Porta M., Quality of life, impaired vision and social role in people with diabetes: a multicenter observational study. Acta Diabetologica 2013 10.1007/s00592-013- 0470-1
9. Skrivarhaug T., Bangstad H. J., Stene L. C., Sandvik L., Hanssen K. F., Joner G., Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006 49 2 298 305 2-s2.0-31844437817 10.1007/s00125-005-0082-6
10. Jacobson A. M., Braffett B. H., Cleary P. A., Gubitosi-Klug R. A., Larkin M. E., The DCCT/EDIC Research Group, The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the diabetes control and complications/epidemiology of diabetes interventions and complications cohort. Diabetes Care 2013 36 10 3131 3138 10.2337/dc12-2109
11. Gomes M. B., de Mattos Matheus A. S., Calliari L. E., Luescher J. L., Manna T. D., Savoldelli R. D., Cobas R. A., Coelho W. S., Tschiedel B., Ramos A. J., Fonseca R. M., Araujo N. B., Almeida H. G., Melo N. H., Jezini D. L., Negrato C. A., Economic status and clinical care in young type 1 diabetes patients: a nationwide multicenter study in Brazil. Acta Diabetologica 2012 10.1007/s00592-012-0404-3
12. Govan L., Wu O., Briggs A., Colhoun H. M., McKnight J. A., Morris A. D., Pearson D. W. M., Petrie J. R., Sattar N., Wild S. H., Lindsay R. S., Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2011 54 8 2000 2008 2-s2.0-79960911682 10.1007/s00125-011-2176-7
13. Kawalec P., Pilc A., A cost-effectiveness analysis of treatment of diabetic complications in 2002. Journal of the Diabetes Poland 2004 1 9 14
14. Tarr J. M., Kaul K., Wolanska K., Kohner E. M., Chibber R., Retinopathy in diabetes. Advances in Experimental Medicine and Biology 2012 771 88 106
15. Klein R., Klein B. E. K., Moss S. E., Cruickshanks K. J., The wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998 105 10 1801 1815 2-s2.0-0031793875 10.1016/S0161-6420(98)91020-X
16. Zorena K., Raczyńska D., Raczyńska K., Immunological risk factors for the development and progression of diabetic retinopathy. Diabetic Retinopathy 2012 Rijeka, Croatia InTech 137 162
17. El-Asrar A. M. A., Nawaz M. I., Kangave D., Siddiquei M. M., Geboes K., Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. Journal of Diabetes Research 2013 2013 9 539658 10.1155/2013/539658
18. Kastelan S., Tomić M., Salopek-Rabatić J., Pavan J., Lukenda A., Gotovac M., Zunec R., The association between the HLA system and retinopathy development in patients with type 1 diabetes mellitus. Collegium Antropologicum 2013 37 supplement 1 65 70
19. Bierhaus A., Hofmann M. A., Ziegler R., Nawroth P. P., AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovascular Research 1998 37 3 586 600 2-s2.0-0032029363 10.1016/S0008-6363(97)00233-2
20. Goh S. Y., Cooper M. E., The role of advanced glycation end products in progression and complications of diabetes. Journal of Clinical Endocrinology and Metabolism 2008 93 4 1143 1152 2-s2.0-42049118293 10.1210/jc.2007-1817
21. Chen M., Curtis T. M., Stitt A. W., Advanced glycation end products and diabetic retinopathy. Current Medicinal Chemistry 2013 44 6 1397 1407 10.1007/s00726-011-1071-3
22. Wang L., Deng Q. Q., Wu X. H., Yu J., Yang X. L., Zhong Y. M., Upregulation of glutamate-aspartate transporter by glial cell line-derived neurotrophic factor ameliorates cell apoptosis in neural retina in streptozotocin-induced diabetic rats. CNS Neuroscience and Therapeutics 2013 10.1111/cns.12150
23. Zong H., Ward M., Madden A., Yong P. H., Limb G. A., Curtis T. M., Stitt A. W., Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010 53 12 2656 2666 2-s2.0-78649333713 10.1007/s00125-010-1900-z
24. Sun Z., Liu J., Zeng X., Huangfu J., Jiang Y., Wang M., Chen F., Protective actions of microalgae against endogenous and exogenous advanced glycation endproducts (AGEs) in human retinal pigment epithelial cells. Food and Function 2011 2 5 251 258 2-s2.0-79957808756 10.1039/c1fo10021a
25. Zhu Y., Shu T., Lin Y., Wang H., Yang J., Shi Y., Han X., Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic β -cells. Biochemical and Biophysical Research Communications 2011 404 1 159 165 2-s2.0-78650890745 10.1016/j.bbrc.2010.11.085
26. Stitt A. W., Curtis T. M., Advanced glycation and retinal pathology during diabetes. Pharmacological Reports 2005 57, supplement 156 168 2-s2.0-33645670376
27. Chilelli N. C., Burlina S., Lapolla A., AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view. Nutrition, Metabolism and Cardiovascular Diseases 2013 10.1016/j.numecd.2013.04.004
28. Mohammad G., Siddiquei M. M., Othman A., Al-Shabrawey M., El-Asrar A. M. A., High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Experimental Eye Research 2013 107 101 109 10.1016/j.exer.2012.12.009
29. Zorena K., Kula M., Malinowska E., Raczyńska D., Myśliwiec M., Raczyńska K., Threshold serum concentrations of tumour necrosis factor α (TNF α) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM). Human Immunology 2013 74 1 75 81 10.1016/j.humimm.2012.10.002
30. Kostolanská J., Jakuš V., Barák L., HbA1c and serum levels of advanced glycation and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 2009 22 5 433 442 2-s2.0-68149105858
31. Kerkeni M., Saïdi A., Bouzidi H., Yahya S. B., Hammami M., Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvascular Research 2012 84 3 378 383 10.1016/j.mvr.2012.07.006
32. Sato E., Nagaoka T., Yokota H., Takahashi A., Yoshida A., Correlation between plasma pentosidine concentrations and retinal hemodynamics in patients with type 2 diabetes. The American Journal of Ophthalmology 2012 153 5 903.e1 909.e1 2-s2.0-84859790408 10.1016/j.ajo.2011.10.020
33. El-Asrar A. M. A., Nawaz M. I., Siddiquei M. M., Al-Kharashi A. S., Kangave D., Mohammad G., High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina. Mediators of Inflammation 2013 2013 11 863036 10.1155/2013/863036
34. Yan S. F., Ramasamy R., Schmidt A. M., Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. Journal of Molecular Medicine 2009 87 3 235 247 2-s2.0-60549110804 10.1007/s00109-009-0439-2
35. Matsumoto Y., Takahashi M., Ogata M., Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. Japanese Journal of Ophthalmology 2002 46 4 406 412 2-s2.0-0036661750 10.1016/S0021-5155(02)00508-7
36. Kula M., Zorena K., Myśliwska J., Transcription factor NF- B-its role in inflammation in diabetes type 1. Family Medicine and Primary Care Review 2011 13 3 592 595 2-s2.0-84856259048
37. Urios P., Grigorova-Borsos A. M., Sternberg M., Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Research and Clinical Practice 2007 77 2 337 340 2-s2.0-34247561163 10.1016/j.diabres.2006.12.024
38. Urios P., Grigorova-Borsos A., Sternberg M., Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose, according to their structure. European Journal of Nutrition 2007 46 3 139 146 2-s2.0-33947679408 10.1007/s00394-007-0644-0
39. Luo D., Fan Y., Xu X., The effects of aminoguanidine on retinopathy in STZ-induced diabetic rats. Bioorganic and Medicinal Chemistry Letters 2012 22 13 4386 4390 10.1016/j.bmcl.2012.04.130
40. El Shazly A. H. M., Mahmoud A. M., Darwish N. S., Potential prophylactic role of aminoguanidine in diabetic retinopathy and nephropathy in experimental animals. Acta Pharmaceutica 2009 59 1 67 73 2-s2.0-63149128708 10.2478/v10007-009-0009-8
41. Ferrara N., Gerber H., LeCouter J., The biology of VEGF and its receptors. Nature Medicine 2003 9 6 669 676 2-s2.0-0037699954 10.1038/nm0603-669
42. Aiello L. P., Wong J. S., Role of vascular endothelial growth factor in diabetic vascular complications. Kidney International Supplements 2000 58 77 S113 S119 2-s2.0-0033852483
43. Ferrara N., Role of vascular endothelial growth factor in regulation of physiological angiogenesis. The American Journal of Physiology-Cell Physiology 2001 280 6 C1358 C1366 2-s2.0-0034979273
44. Adamis A. P., Miller J. W., Bernal M. T., D'Amico D. J., Folkman J., Yeo T. K., Yeo K. T., Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. The American Journal of Ophthalmology 1994 118 4 445 450 2-s2.0-0028123090
45. Simó R., Carrasco E., García-Ramírez M., Hernández C., Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Current Diabetes Reviews 2006 2 1 71 98 10.2174/157339906775473671
46. Wirostko B., Wong T. Y., Simó R., Vascular endothelial growth factor and diabetic complications. Progress in Retinal and Eye Research 2008 27 6 608 621 2-s2.0-55849126672 10.1016/j.preteyeres.2008.09.002
47. Mohammad G., Kowluru R. A., Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9. Journal of Cellular Physiology 2012 227 3 1052 1061 10.1002/jcp.22822
48. Chiarelli F., Spagnoli A., Basciani F., Tumini S., Mezzetti A., Cipollone F., Cuccurullo F., Morgese G., Verrotti A., Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabetic Medicine 2000 17 9 650 656 2-s2.0-0033782589 10.1046/j.1464-5491.2000.00350.x
49. Myśliwiec M., Balcerska A., Zorena K., Myśliwska J., Lipowski P., Raczyńska K., The assessment of the correlation between vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF- α), interleukin 6 (IL-6), glycaemic control (HbA1c) and the development of the diabetic retinopathy in children with diabetes mellitus type 1. Klinika Oczna 2007 109 4-6 150 154 2-s2.0-34447527119
50. Zorena K., Myśliwska J., Myśliwiec M., Balcerska A., Lipowski P., Raczyńska K., Interleukin-12, vascular endothelial growth factor and tumor necrosis factor- α in the process of neoangiogenesis of diabetic retinopathy in children. Klinika Oczna 2007 109 4-6 155 159 2-s2.0-34447519922
51. Zorena K., Myśliwska J., Myśliwiec M., Rybarczyk-Kapturska K., Malinowska E., Wiśniewski P., Raczyńska K., Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus. Journal of Human Hypertension 2010 24 11 755 762 10.1038/jhh.2010.7
52. Lu M., Adamis A. P., Molecular biology of choroidal neovascularization. Ophthalmology Clinics of North America 2006 19 3 323 334 2-s2.0-33748786807 10.1016/j.ohc.2006.05.001
53. Sultan M. B., Zhou D., Loftus J., Dombi T., Ice K. S., A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011 118 6 1107 1118 2-s2.0-79958012399 10.1016/j.ophtha.2011.02.045
54. Gordon M. S., Cunningham D., Managing patients treated with bevacizumab combination therapy. Oncology 2005 69 3 25 33 2-s2.0-27944456516 10.1159/000088481
55. van Meter M. E., Kim E. S., Bevacizumab: current updates in treatment. Current Opinion in Oncology 2010 22 6 586 591 10.1097/CCO.0b013e32833edc0c
56. Benhmidoune L., McHachi A., Boukhrissa M., Chakib A., Rachid R., Elbelhadji M., Amraoui A., Use of bevacizumab in the treatment of complicated proliferative diabetic retinopathy. Journal Français d'Ophtalmologie 2013 10.1016/j.jfo.2012.11.015
57. Arevalo J. F., Fromow-Guerra J., Sanchez J. G., Maia M., Berrocal M. H., Wu L., Saravia M. J., Costa R. A., Pan-American Collaborative Retina Study Group, Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American collaborative retina study group at 12 months follow-up. Retina 2008 28 10 1387 1394 2-s2.0-58949093226 10.1097/IAE.0b013e3181884ff4
58. Tokgöz O., Sahin A., Tüfek A., Cnar Y., Güzel A., Ciftçi T., Celik F., Yüksel H., Inhalation anesthesia with sevoflurane during intravitreal bevacizumab injection in infants with retinopathy of prematurity. BioMed Research International 2013 2013 4 435387 10.1155/2013/435387
59. Suzuki Y., Suzuki K., Yokoi Y., Miyagawa Y., Metoki T., Nakazawa M., Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy. Retina 2013 10.1097/IAE.0b013e3182979df6
60. Gangaputra S., Almukhtar T., Glassman A. R., Aiello L. P., Bressler N., Bressler S. B., Danis R. P., Davis M. D., Diabetic Retinopathy Clinical Research Network, Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. Investigative Ophthalmology and Visual Science 2011 52 9 6168 6173 2-s2.0-80051532218 10.1167/iovs.11-7321
61. Thomas B. J., Shienbaum G., Boyer D. S., Flynn H. W. Jr., Evolving strategies in the management of diabetic macular edema: clinical trials and current management. Canadian Journal of Ophthalmology 2013 48 1 22 30 10.1016/j.jcjo.2012.11.012
62. Nguyen Q. D., Tatlipinar S., Shah S. M., Haller J. A., Quinlan E., Sung J., Zimmer-Galler I., Do D. V., Campochiaro P. A., Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. The American Journal of Ophthalmology 2006 142 6 961.e4 969.e4 2-s2.0-33845191304 10.1016/j.ajo.2006.06.068
63. Do D. V., Nguyen Q. D., Shah S. M., Browning D. J., Haller J. A., Chu K., Yang K., Cedarbaum J. M., Vitti R. L., Ingerman A., Campochiaro P. A., An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. The British Journal of Ophthalmology 2009 93 2 144 149 2-s2.0-60849129118 10.1136/bjo.2008.138271
64. Nguyen Q. D., Shah S. M., Khwaja A. A., Channa R., Hatef E., Do D. V., Boyer D., Heier J. S., Abraham P., Thach A. B., Lit E. S., Foster B. S., Kruger E., Dugel P., Chang T., Das A., Ciulla T. A., Pollack J. S., Lim J. I., Eliot D., Campochiaro P. A., Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010 117 11 2146 2151 2-s2.0-78049293726 10.1016/j.ophtha.2010.08.016
65. Brown D. M., Nguyen Q. D., Marcus D. M., Boyer D. S., Patel S., Feiner L., Schlottmann P. G., Rundle A. C., Zhang J., Rubio R. G., Adamis A. P., Ehrlich J. S., Hopkins J. J., RIDE, RISE Research Group, Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013 10.1016/j.ophtha.2013.02.034
66. Stewart M. W., Rosenfeld F. J., Predicted biological activity of intravitreal VEGF Trap. The British Journal of Ophthalmology 2008 92 5 667 668 2-s2.0-43649083100 10.1136/bjo.2007.134874
67. Do D. V., Nguyen Q. D., Boyer D., Schmidt-Erfurth U., Brown D. M., Vitti R., Berliner A. J., Gao B., Zeitz O., Ruckert R., Schmelter T., Sandbrink R., Heier J. S., DA VINCI Study Group, One-year outcomes of the DA VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012 119 8 1658 1665 2-s2.0-84859937024 10.1016/j.ophtha.2012.02.010
68. Holz F. G., Amoaku W., Donate J., Guymer R. H., Kellner U., Schlingemann R. O., Weichselberger A., Staurenghi G., SUSTAIN Study Group, Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011 118 4 663 671 2-s2.0-79953295148 10.1016/j.ophtha.2010.12.019
69. Englander M., Chen T. C., Paschalis E. I., Miller J. W., Kim I. K., Intravitreal injections at the Massachusetts eye and ear infirmary: analysis of treatment indications and postinjection endophthalmitis rates. The British Journal of Ophthalmology 2013 97 4 460 465 10.1136/bjophthalmol-2012-302435
70. Sukhanov S., Higashi Y., Shai S. Y., Vaughn C., Mohler J., Li Y., Song Y., Titterington J., Delafontaine P., IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 12 2684 2690 2-s2.0-36349028053 10.1161/ATVBAHA.107.156257
71. Sun X., Huang L., Zhang M., Sun S., Wu Y., Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3 β Toxicology 2010 271 1-2 5 12 2-s2.0-77951296766 10.1016/j.tox.2010.01.001
72. Goes N., Urmson J., Vincent D., Ramassar V., Halloran P. F., Effect of recombinant human insulin-like growth factor-1 on the inflammatory response to acute renal injury. Journal of the American Society of Nephrology 1996 7 5 710 720 2-s2.0-0030357269
73. Löfqvist C., Engström E., Sigurdsson J., Hård A. L., Niklasson A., Ewald U., Holmström G., Smith L. E., Hellström A., Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit. Pediatrics 2006 117 6 1930 1938 10.1542/peds.2005-1926
74. Pérez-Muñuzuri A., Fernández-Lorenzo J. R., Couce-Pico M. L., Blanco-Teijeiro M. J., Fraga-Bermúdez J. M., Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatrica 2010 99 4 519 525 2-s2.0-77649219087 10.1111/j.1651-2227.2009.01677. x
75. Peczyńska J., Urban M., Urban B., Głowińska B., Florys B., Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy. Pediatric Endocrinology, Diabetes and Metabolism 2004 10 1 41 48
76. Wdrychowicz A., Dziatkowiak H., Nazim J., Sztefko K., Insulin-like growth factor-1 and its binding proteins, IGFBP-1 and IGFBP-3, in adolescents with type-1 diabetes mellitus and microalbuminuria. Hormone Research 2005 63 5 245 251 2-s2.0-22544466697 10.1159/000085941
77. Santilli F., Spagnoli A., Mohn A., Tumini S., Verrotti A., Cipollone F., Mezzetti A., Chiarelli F., Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. Journal of Clinical Endocrinology and Metabolism 2001 86 8 3871 3876 2-s2.0-0034889879 10.1210/jc.86.8.3871
78. Simó R., Lecube A., Segura R. M., García Arumí J., Hernández C., Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. The American Journal of Ophthalmology 2002 134 3 376 382 2-s2.0-0036742892 10.1016/S0002-9394(02)01538-6
79. Hartnett M. E., Tinkham N., Paynter L., Geisen P., Rosenberg P., Koch G., Cohen K. L., Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. The American Journal of Ophthalmology 2009 148 6 895.e1 901.e1 2-s2.0-70449628897 10.1016/j.ajo.2009.07.014
80. Burgos R., Mateo C., Cantón A., Hernández C., Mesa J., Simó R., Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care 2000 23 1 80 83 2-s2.0-0033961452
81. Hernández C., Simó R., Neuroprotection in diabetic retinopathy. Current Diabetes Reports 2012 12 4 329 337 10.1007/s11892-012-0284- 5
82. Vigneswara V., Berry M., Logan A., Ahmed Z., Pigment epithelium-derived factor is retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury. Investigative Ophthalmology and Visual Science 2013 54 4 2624 2633 10.1167/iovs.13-11803
83. Tombran-Tink J., PEDF in angiogenic eye diseases. Current Molecular Medicine 2010 10 3 267 278 2-s2.0-77951078456 10.2174/156652410791065336
84. Doll J. A., Stellmach V. M., Bouck N. P., Bergh A. R. J., Lee C., Abramson L. P., Cornwell M. L., Pins M. R., Borensztajn J., Crawford S. E., Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nature Medicine 2003 9 6 774 780 2-s2.0-0038240367 10.1038/nm870
85. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Takeuchi M., Inoue H., Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvascular Research 2003 65 3 186 190 2-s2.0-0037404757 10.1016/S0026-2862(03)00005-0
86. Dawson D. W., Volpert O. V., Gillis P., Crawford S. E., Xu H., Benedict W., Bouck N. P., Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999 285 5425 245 248 2-s2.0-0033538517 10.1126/science.285.5425.245
87. Cai J., Wu L., Qi X., Calzi S., Caballero S., Shaw L., Ruan Q., Grant M. B., Boulton M. E., PEDF regulates vascular permeability by a γ -secretase-mediated pathway. PLoS ONE 2011 6 6 2-s2.0-79959217449 10.1371/journal.pone.0021164 e21164
88. Volpert O. V., Zaichuk T., Zhou W., Reiher F., Ferguson T. A., Stuart P. M., Amin M., Bouck N. P., Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nature Medicine 2002 8 4 349 357 2-s2.0-0036104828 10.1038/nm0402-349
89. Subramanian P., Crawford S. E., Becerra S. P., Assays for the antiangiogenic and neurotrophic serpin pigment epithelium-derived factor. Methods in Enzymology 2011 499 183 204 2-s2.0-79959344654 10.1016/B978-0-12- 386471-0.00010-9
90. Matsunaga N., Chikaraishi Y., Izuta H., Ogata N., Shimazawa M., Matsumura M., Hara H., Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 2008 115 11 1916 1922 2-s2.0-54949090327 10.1016/j.ophtha.2008.06.025
91. Shen X., Xie B., Cheng Y., Jiao Q., Zhong Y., Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocular Immunology and Inflammation 2011 19 4 246 254 2-s2.0-79960675357 10.3109/09273948.2011.580073
92. Ishibashi Y., Matsui T., Ohta K., Tanoue R., Takeuchi M., Asanuma K., Fukami K., Okuda S., Nakamura K., Yamagishi S., PEDF inhibits AGE-induced podocyte apoptosis via PPAR- γ activation. Microvascular Research 2013 85 54 58. Erratum in Microvascular Research, vol. 87, p. 100, 2013 10.1016/j.mvr.2012.10.007
93. Orlova V. V., Liu Z., Goumans M., Dijke P. T., Controlling angiogenesis by two unique TGF- β type I receptor signaling pathways. Histology and Histopathology 2011 26 9 1219 1230 2-s2.0-80053186583
94. Pot I., Patel S., Deng L., Chandhoke A. S., Zhang C., Bonni A., Bonni S., Identification of a novel link between the protein kinase NDR1 and TGF β signaling in epithelial cells. PLoS ONE 2013 8 6 e67178 10.1371/journal.pone. 0067178
95. Yang D., Baumann J. M., Sun Y. Y., Tang M., Dunn R. S., Akeson A. L., Kernie S. G., Kallapur S., Lindquist D. M., Huang E. J., Potter S. S., Liang H. C., Kuan C. Y., Overexpression of vascular endothelial growth factor in the germinal matrix induces neurovascular proteases and intraventricular hemorrhage. Science Translational Medicine 2013 5 193 193ra90 10.1126/scitranslmed.3005794
96. Weiss A., Attisano L., The TGF β superfamily signaling pathway. Wiley Interdisciplinary Reviews: Developmental Biology 2013 2 1 47 63 10.1002/wdev.86
97. Yang I. V., Epigenomics of idiopathic pulmonary fibrosis. Epigenomics 2012 4 2 195 203 2-s2.0-84859203603 10.2217/epi.12.10
98. Zorena K., Malinowska E., Raczyńska D., Myśliwiec M., Raczyńska K., Serum concentrations of transforming growth factor- β 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus. Journal of Diabetes Research 2013 2013 6 614908 10.1155/2013/614908
99. Zorena K., Raczyńska D., Wiśniewski P., Malinowska E., Myśliwiec M., Raczynska K., Rachoń D., Relationship between serum transforming growth factor β 1 (TGF- β 1) concentrations and the duration of type 1 diabetes mellitus (T1DM) in children and adolescents. Mediators of Inflammation. In press
100. Agarwal R., Agarwal P., Future target molecules in antiglaucoma therapy: TGF- β may have a role to play. Ophthalmic Research 2009 43 1 1 10 2-s2.0-70349890473 10.1159/000246571
101. Losso J. N., Truax R. E., Richard G., Trans-resveratrol inhibits hyperglycemia-induced inflammation and connexin downregulation in retinal pigment epithelial cells. Journal of Agricultural and Food Chemistry 2010 58 14 8246 8252 2-s2.0-77954878032 10.1021/jf1012067
102. Majewska-Szczepanik M., Paust S., von Andrian U. H., Askenase P. W., Szczepanik M., Natural killer cell-mediated contact sensitivity develops rapidly and depends on interferon- α interferon- γ and interleukin-12. Immunology 2013 140 1 98 110 10.1111/imm.12120
103. Rothe H., Burkart V., Faust A., Kolb H., Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice. Diabetologia 1996 39 1 119 122 2-s2.0-0030032393
104. Kang B. Y., Kim T. S., Targeting cytokines of the interleukin-12 family in autoimmunity. Current Medicinal Chemistry 2006 13 10 1149 1156 2-s2.0-33646001437 10.2174/092986706776360879
105. Duda D. G., Sunamura M., Lozonschi L., Kodama T., Egawa S., Matsumoto G., Shimamura H., Shibuya K., Takeda K., Matsuno S., Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Research 2000 60 4 1111 1116 2-s2.0-0034652459
106. Ghiringhelli F., Ménard C., Martin F., Zitvogel L., The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunological Reviews 2006 214 1 229 238 2-s2.0-33750691006 10.1111/j.1600-065X.2006.00445.x
107. Colombo M. P., Trinchieri G., Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine and Growth Factor Reviews 2002 13 2 155 168 2-s2.0-0036005890 10.1016/S1359-6101(01)00032-6
108. Zorena K., Myśliwska J., Myśliwiec M., Balcerska A., Lipowski P., Raczyńska K., Interleukin-12 and tumour necrosis factor- α equilibrium is a prerequisite for clinical course free from late complications in children with type 1 diabetes mellitus. Scandinavian Journal of Immunology 2008 67 2 204 208 2-s2.0-38149075082 10.1111/j.1365-3083.2007.02054. x
109. Wegner M., Araszkiewicz A., Pioruńska-Mikołajczak A., Zozulińska-Ziółkiewicz D., Wierusz-Wysocka B., Pioruńska-Stolzmann M., The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clinical Biochemistry 2009 42 16-17 1621 1627 10.1016/j.clinbiochem.2009.07.023
110. Antunica A. G., Karaman K., Znaor L., Sapunar A., Buško V., Puzović V., IL-12 concentrations in the aqueous humor and serum of diabetic retinopathy patients. Graefe's Archive for Clinical and Experimental Ophthalmology 2012 250 6 815 821 10.1007/s00417-011-1905-4
111. Zhu Y., Hu C., Lu M., Liao S., Marini J. C., Yohrling J., Yeilding N., Davis H. M., Zhou H., Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. Journal of Clinical Pharmacology 2009 49 2 162 175 2-s2.0-58849118867 10.1177/0091270008329556
112. Buckland J., Therapy: ustekinumab therapeutic effects-more than skin deep. Nature Reviews Rheumatology 2013 9 8 445 10.1038/nrrheum.2013.106
113. Bigda J., Beletsky I., Brakebusch C., Varfolomeev Y., Engelmann H., Bigda J., Holtmann H., Wallach D., Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. Journal of Experimental Medicine 1994 180 2 445 460 2-s2.0-0028337454 10.1084/jem.180.2.445
114. Arita R., Nakao S., Kita T., Kawahara S., Asato R., Yoshida S., Enaida H., Hafezi-Moghadam A., Ishibashi T., A key role for ROCK in TNF- α -mediated diabetic microvascular damage. Investigative Ophthalmology and Visual Science 2013 54 3 2373 2383 10.1167/iovs.12-10757
115. Zorena K., Myśliwiec M., Rybarczyk K., Malinowska E., Hak Ł., Raczyńska-Woźniak D., Raczyńska K., Balcerska A., Myśliwska J., Proangiogenic effects of tumor necrosis factor- α (TNF- α) in diabetes mellitus children. Family Medicine and Primary Care Review 2008 10 3 745 748
116. Zorena K., Myśliwska J., Myśliwiec M., Balcerska A., Hak Ł., Lipowski P., Raczyńska K., Serum TNF- α level predicts nonproliferative diabetic retinopathy in children. Mediators of Inflammation 2007 2007 5 2-s2.0-34250836383 10.1155/2007/92196 92196
117. Gustavsson C., Agardh E., Bengtsson B., Agardh C., TNF- α is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. Journal of Diabetes and its Complications 2008 22 5 309 316 2-s2.0-42549108719 10.1016/j.jdiacomp.2007.03.001
118. Koleva-Georgieva D. N., Sivkova N. P., Terzieva D., Serum inflammatory cytokines IL-1 β IL-6, TNF- α and VEGF have influence on the development of diabetic retinopathy. Folia medica 2011 53 2 44 50 2-s2.0-80051926407
119. Adamiec-Mroczek J., Oficjalska-Młyńczak J., Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes-role of the inflammatory-immune process in
120. Reiff A., Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis and Rheumatism 2003 48 7 2079 2080 2-s2.0-0038678970 10.1002/art.11155
121. Sfikakis P. P., Behçet's disease: a new target for anti-tumour necrosis factor treatment. Annals of the Rheumatic Diseases 2002 61 supplement 2 ii51 ii53 2-s2.0-0036838908
122. Lim L. L., Fraunfelder F. W., Rosenbaum J. T., Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis and Rheumatism 2007 56 10 3248 3252 2-s2.0-35348914933 10.1002/art.22918
123. Calabrese L. H., Molecular differences in anticytokine therapies. Clinical and Experimental Rheumatology 2003 21 2 241 248 2-s2.0-0037366864
124. Yoshida A., Kaburaki T., Okinaga K., Takamoto M., Kawashima H., Fujino Y., Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Japanese Journal of Ophthalmology 2012 56 6 536 543 10.1007/s10384-012-0182-z
125. Verma S., Kroeker K. I., Fedorak R. N., Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature. BMC Gastroenterology 2013 13 article 59 10.1186/1471-230X-13-59
126. Benucci M., Saviola G., Manfredi M., Sarzi-Puttini P., Atzeni F., Tumor necrosis factors blocking agents: analogies and differences. Acta Bio Medica 2012 83 1 72 80
127. Petropoulos I. K., Vaudaux J. D., Guex-Crosier Y., Anti-TNF- α therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klinische Monatsblatter fur Augenheilkunde 2008 225 5 457 461 2-s2.0-47649109914 10.1055/s-2008-1027361
128. Wu L., Hernandez-Bogantes E., Roca J. A., Arevalo J. F., Barraza K., Lasave A. F., Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American collaborative retina study group. Retina 2011 31 2 298 303 2-s2.0-79551528030 10.1097/IAE.0b013e3181eac7a6
129. Biswas N. R., Das G. K., Dubey A. K., Monoclonal antibodies in ophthalmology. Nepal Medical College Journal 2010 12 4 264 271 2-s2.0-79960991940
130. Donnithorne K. J., Read R. W., Lowe R., Weiser P., Cron R. Q., Beukelman T., Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report. Pediatric Rheumatology Online Journal 2013 11 1 25 10.1186/1546-0096-11-25
131. Foster C. S., Chang P. Y., Ahmed A. R., Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. A preliminary report. Ophthalmology 2010 117 5 861 869 2-s2.0-77951623575 10.1016/j.ophtha.2009.09.049
132. Shono E., Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis. Drugs in R&D 2013 13 1 95 100
133. Owczarek D., Cibor D., Szczepanek M., Mach T., Biological therapy of inflammatory bowel disease. Polish Archives of Internal Medicine 2009 119 1-2 84 88 2-s2.0-61349111301
134. Beck A., Wurch T., Reichert J. M., 6th annual European antibody congress 2010: November 29-December 1, 2010, Geneva, Switzerland. MAbs 2011 3 2 111 132 2-s2.0-79952713568 10.4161/mabs.3.2.14788
135. Marticorena-Álvarez P., Chaparro M., Pérez-Casas A., Muriel-Herrero A., Gisbert J. P., Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease. Journal of Crohn's and Colitis 2012 6 9 950 953 2-s2.0-84859931664 10.1016/j.crohns.2012.03.015
136. Mesquida M., Molins B., Llorenç V., Hernández M. V., Espinosa G., Dick A. D., Adán A., Current and future treatments for Behçet's uveitis: road to remission. International Ophthalmology 2013 10.1007/s10792-013-9788-5